• Publications
  • Influence
Oxidative stress is progressively enhanced with advancing stages of CKD.
BACKGROUND Oxidative stress appears to have a central role in the pathophysiological process of uremia and its complications, including cardiovascular disease. However, there is little evidence toExpand
  • 284
  • 16
  • PDF
Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase.
It is well established that inflammation is an integral feature of atherosclerosis and of the cardiovascular diseases which it underlies. Oxidative stress is also recognized as a key actor inExpand
  • 304
  • 13
Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment – a prospective, controlled study
We investigated lipid profiles and lipoprotein modification after immuno-intervention in patients with early rheumatoid arthritis (ERA). Fifty-eight patients with ERA who met the American College ofExpand
  • 234
  • 13
The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma.
Platelet-activating factor (PAF) acetylhydrolase exhibits a Ca(2+)-independent phospholipase A2 activity and degrades PAFas well as oxidized phospholipids (oxPL). Such phospholipids are accumulatedExpand
  • 138
  • 12
Biocatalytic preparation of acylated derivatives of flavonoid glycosides enhances their antioxidant and antimicrobial activity.
Enzymatic synthesis of acylated derivatives of a monosaccharidic flavonoid chrysoeriol-7-O-beta-D-(3''-E-p-coumaroyl)-glucopyranoside as well as of a disaccharidic flavonoidExpand
  • 117
  • 8
Amyloid-beta (1-40) and the risk of death from cardiovascular causes in patients with coronary heart disease.
BACKGROUND The amyloid beta peptide is the major protein constituent of neuritic plaques in Alzheimer disease and appears to play a central role in vascular inflammation pathophysiology. OBJECTIVESExpand
  • 60
  • 6
  • PDF
"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses.
Aim of the present Consensus Statement is to provide a comprehensive and up to-date document on the pathophysiology, atherogenicity and clinical significance of low density liproproteins (LDL)Expand
  • 170
  • 5
Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma.
BACKGROUND Recent clinical studies showed that lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) is a predictor for incident atherosclerotic disease. We have previously shown that among the LDLExpand
  • 172
  • 5
  • PDF
Differential Effect of Hypolipidemic Drugs on Lipoprotein-Associated Phospholipase A2
Objective— Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a predictor for incident atherosclerotic disease. We investigated the effect of 3 hypolipidemic drugs that exert their action throughExpand
  • 131
  • 5
  • PDF
Apolipoprotein(a) phenotypes and lipoprotein(a) concentrations in patients with renal failure.
Patients with renal failure have an increased incidence of atherosclerotic disease. Numerous studies have shown that these patients show increased serum lipoprotein(a) [Lp(a)] concentrations comparedExpand
  • 48
  • 5
  • PDF